Healthcare / BiotechnologyNasdaqGS
$8.22
-0.30 (-3.52%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-116.5M · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$500M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-69.4%
↓Gross Margin
N/A
•Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.96x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-161.3M · FCF $-154.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | — | $7.0M |
| Net Income | $-161.3M | $-161.3M | $-127.5M | $-60.4M | $-28.9M |
| EBITDA | $-159.0M | $-159.0M | $-125.2M | $-58.5M | $-27.8M |
| EPS | -3.64 | -3.64 | -3.33 | -1.48 | -1.12 |
| Operating Margin | — | — | — | — | -418.3% |
| Net Margin | — | — | — | — | -411.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.12 | 0.12 | 0.03 | -0.07 | -0.14 |
| Current Ratio | 8.15 | 8.15 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-154.8M | $-154.8M | $-116.5M | $-53.0M | $-36.9M |
| Returns | |||||
| ROE | -69.4% | -69.4% | -47.8% | 45.9% | 39.0% |
| Valuation | |||||
| P/B | 1.57 | 1.57 | 0.59 | — | — |
| Growth & Yield | |||||
| EPS Growth | -9.3% | -9.3% | -125.2% | -32.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+222.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.33 → -3.64
Residual
+222.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.